NSCLC
Conditions
Interventions
Experiment group:Kang ai injection 60 ml ivgtt D1-14 Q21d, combined with mono-chemotherapy
Control group:platinum-based doublet chemotherapy
Sponsors
Guang’anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of stage III-IV NSCLC according to pathology or cytology; 2. At least 1 objectively measurable Tumor lesion, maximum diameter>=20mm(via X-ray) or>=10mm (via CT); 3. ECOG PS score 0-2; 4. Expected survival>= 3 months; 5. Aged from 60 ~ 75; 6. Without operation indication or unwilling to surgical treatment; 7. with the indications of chemotherapy; 8. has stoped radiotherapy chemotherapy for at least 1 month; 9. Signed informed consent, with good compliance.
Exclusion criteria
Exclusion criteria: 1. Only with immeasurable lesions such as pleural effusion,pulmonary lymphangitic carcinomatosis, ascites, peritoneal cancer lesions, diffuse hepatic involvement, bone metastasis; 2. Patients with severe,uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy; 3. using other experimental drugs or paticipate in other clinical trials at the same time; 4. patients allergic to the test drug; 5. psychiatric patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate (DCR), Response Rate (RR), Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS), Adverse Reactions, Clinical Symptoms, Weight, PS score, Quality of Life, Immunologic Function, Tumor Marker; | — |
Countries
China
Contacts
Public ContactHongsheng Lin
Guang'anmen Hospital affiliatied to China Academy of Chinese Medical Sciences
Outcome results
None listed